Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2199 participants.
Also called NCT02072434
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 2,199 participants
- Sponsor
- Registry
-
NCT02072434 -
2013-003148-21
-
- Other papers using this trial's data
- Edoxaban therapy increases treatment satisfaction and reduces utilization of healthcare resources: an analysis from the EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of atrial fibrillation (ENSURE-AF) study
- Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Austria, Belgium, Bulgaria, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Netherlands, Poland, Romania, Russia, Spain, Sweden, Ukraine, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02072434. Randomized; no masking; primary purpose treatment. Start 2014-03-25 (actual); primary completion 2016-02-03 (actual). Results posted on 2019-03-13.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)
- Acronym
- ENSURE-AF
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- Edoxaban
- Intervention (Drug)
- Warfarin
- Intervention (Drug)
- Enoxaparin
- Lead sponsor
- Daiichi Sankyo
Record details
- Record id
cardio:ct-nct02072434- Content hash
48350a115f029f2fa42d9ee54c34c735b84aa908e4fcd58146641dab2c83f951